healthneutral
Breast Cancer: The Lymphocyte Link
Friday, February 14, 2025
However, it's not all good news. The trial also showed that some patients with low TILs still did well. This means that TILs are not the only factor that determines survival. Other factors, like the stage of the cancer and the patient's overall health, also play a role. So, while TILs are a promising marker, they are not a magic bullet.
The ShortHER trial is a step forward in understanding how the immune system can help fight cancer. It shows that the body's own defenses can be a powerful tool in the fight against cancer. But it also shows that there is still a lot to learn. Doctors and researchers will continue to study TILs and other markers to find the best ways to treat breast cancer. This is a critical step in the fight against cancer. It is important to remember that every patient is different, and what works for one may not work for another. This is why personalized medicine is so important.
Actions
flag content